Influenza surface proteins

Influenza surface proteins, primarily Hemagglutinin (HA), Neuraminidase (NA), and the Matrix 2 (M2) ion channel, are the essential components of the influenza virus envelope that facilitate infection and replication. Hemagglutinin mediates the initial attachment of the virus to host cell sialic acid receptors and triggers membrane fusion for viral entry (UniProt: P03468). Neuraminidase acts as an enzyme that cleaves sialic acid residues, allowing newly formed virions to be released from the host cell surface and spread to adjacent cells (UniProt: P03474). The M2 protein forms a proton-selective channel that acidifies the viral interior, a process required for the release of the viral genome into the host cytoplasm (UniProt: P06821). These proteins are the primary targets for the human immune response and pharmacological interventions, including seasonal vaccines and antiviral drugs like neuraminidase inhibitors (StatPearls: Influenza Antivirals). However, the high rate of mutation in these proteins, known as antigenic drift, poses a significant challenge for long-term therapeutic efficacy and necessitates annual vaccine reformulation. Drugs such as oseltamivir and zanamivir target the enzymatic activity of NA, while older adamantanes target the M2 channel, though widespread resistance has limited the latter's clinical utility (Nature Reviews Microbiology: doi:10.1038/nrmicro.2017.118).

Other names

Viral surface glycoproteinsInfluenza envelope proteinsHA/NA/M2 proteinsInfluenza virus surface antigens

Neuraminidase inhibition to prevent viral release; M2 ion channel blockade to prevent viral uncoating; Hemagglutinin inhibition to prevent viral attachment and fusion.